IgE-mediated Allergy to Pembrolizumab and Successful Desensitization

Torrado, I; Peña, M. I; Tsopana, A; Mendoza, I; Beitia, J. M; Mateo, B; Chara, L. E; Vega, A

Torrado, I; Peña, M. I; Tsopana, A; Mendoza, I; Beitia, J. M; Mateo, B; Chara, L. E; Vega, A.

Affiliation

Torrado, I; University Hospital of Guadalajara. Allergy Department. Spain
Peña, M. I; University Hospital of Guadalajara. Allergy Department. Spain
Tsopana, A; University Hospital of Guadalajara. Allergy Department. Spain
Mendoza, I; Pharmacy Department. University Hospital of Guadalajara. Spain
Beitia, J. M; University Hospital of Guadalajara. Allergy Department. Spain
Mateo, B; University Hospital of Guadalajara. Allergy Department. Spain
Chara, L. E; University Hospital of Guadalajara. Oncology Department. Spain
Vega, A; University Hospital of Guadalajara. Allergy Department. Spain

J. investig. allergol. clin. immunol ; 33(4): 304-306, 2023. tab

Article in En | IBECS | ID: ibc-223549

Responsible library: ES1.1

Localization: ES15.1 - BNCS

Subject(s)

Humans; Male; Aged; Desensitization, Immunologic/methods; Antibodies, Monoclonal, Humanized/adverse effects; Drug Hypersensitivity/diagnosis; Drug Hypersensitivity/etiology; Hypersensitivity, Immediate; Antibodies, Monoclonal, Humanized/therapeutic use; Carcinoma, Non-Small-Cell Lung/drug therapy; Lung Neoplasms/drug therapy

Key words

Pembrolizumab; Allergy; Desensitization; Lung cancer; Anti PD-1 antibody; Penbrolizumab; Alergia; Desensibilización; Cáncer de pulmón; Anticuerpo anti PD-1

Fulltext

Add to My VHL

XML

Search on Google

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Desensitization, Immunologic / Drug Hypersensitivity / Antibodies, Monoclonal, Humanized / Hypersensitivity, Immediate Limits: Aged / Humans / Male Language: En Journal: J. investig. allergol. clin. immunol Year: 2023 Document type: Article

Fulltext

Add to My VHL

XML

Search on Google